凯睿思生命科学
CAI
30.56
-1.20
-3.78%
凯睿思生命科学
US · CAI
#1669 按市值排名
上市于 2025
30.56
-1.20
-3.78%
实时 - 追踪5344个代码 - 心跳于121秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 60.92% +0.20pp
- 机构数量
- 296 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Individual/Insider48.80%
Mutual Fund31.00%
Hedge Fund12.20%
VC/PE Fund9.57%
Private Company5.18%
Public Company1.39%
Family Office/Trust0.72%
Government Pension Fund0.66%
Insurance Company0.18%
主要股东 截至 2026-05-15
David Halbert
43.39% · 122.61M 股
FMR
10.94% · 30.92M 股
J.H. Whitney Capital Partners, LLC
3.98% · 11.26M 股
Peter Castleman
3.77% · 10.65M 股
Coatue Management
3.47% · 9.82M 股
Adapt I Ltd.
3.02% · 8.53M 股
Braidwell LP
2.92% · 8.26M 股
Sixth Street Partners, LLC
2.59% · 7.33M 股
PointState Capital LP
2.42% · 6.83M 股
J.P. Morgan Asset Management, Inc.
2.22% · 6.29M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 18次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| David Halbert | Chairman, CEO & Founder | 43.39% |
| Peter Castleman | Lead Independent Director | 3.77% |
| Jon Halbert | Director | 0.52% |
| David Spetzler | President | 0.42% |
| Brian Brille | Executive Vice Chairman & Executive VP | 0.19% |
| George Poste | Vice Chairperson | 0.19% |
| Laurie Johansen | Independent Director | 0.11% |
| Jonathan Kenneth Knowles | Independent Vice Chairperson | 0.10% |
| T. Phillips | -- | 0.04% |
| J. Denton | Senior Vice President | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-21 | J. Denton | Senior Vice President | Open Market Disposition | -7,500 | $31.82 |
| 2026-09-16 | Brian Brille | Executive Vice Chairman & Executive VP | Derivative Exercise and Sale | -400,000 | $2.44–30.33 |
| 2026-09-03 | David Spetzler | President | Derivative Exercise and Sale | -597,212 | $2.44–25.32 |
| 2026-09-03 | David Spetzler | President | Derivative Exercise and Retained | +652,788 | $2.44 |
| 2026-09-03 | David Spetzler | President | Intent to Sell (Form 144) | -119,212 | $24.76 |
| 2026-09-02 | David Spetzler | President | Intent to Sell (Form 144) | -478,000 | $24.86 |
| 2026-08-13 | Peter Castleman | Lead Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Jon Halbert | Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | T. Phillips | -- | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Laurie Johansen | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Lloyd Minor | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | David Fredrickson | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Jeffrey Vacirca | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-13 | Joseph Gilliam | Independent Director | Other Acquisition | +13,192 | -- |
| 2026-08-06 | George Poste | Vice Chairperson | Intent to Sell (Form 144) | -30,000 | $21.42 |
| 2026-08-02 | George Poste | Vice Chairperson | Intent to Sell (Form 144) | -20,000 | $16.25 |
| 2026-05-28 | George Poste | Vice Chairperson | Other Acquisition | +1,600 | $15.62 |
| 2026-05-28 | Jonathan Kenneth Knowles | Independent Vice Chairperson | Other Acquisition | +1,600 | $15.62 |
| 2026-05-14 | David Halbert | Chairman, CEO & Founder | Sale to Issuer | -40,712 | $15.25 |
| 2026-05-14 | Jon Halbert | Director | Open Market Acquisition | +68,000 | $14.56 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:23 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
凯睿思生命科学 讨论区 0 条评论